From Risk to Reward: A Next-Gen Approach to Vendor Risk Management
– A webinar for Clinical Trial Sponsors –
A webinar to help clinical trial Sponsors discover how to build an effective risk-based approach into their vendor management practices.
Industry experts with extensive clinical trial experience discuss how to develop a risk strategy that enhances compliance, reduces vendor qualification inefficiencies, and accelerates clinical trial start-up times.
Access the webinar to gain practical advice and see what tools can be implemented to bring your risk management activities to life.
Key Takeaways:
- Streamline Qualification: Significantly reduce qualification inefficiencies with fast access to up-to-date vendor qualification data. Break the status quo with a more efficient FDA-accepted model.
- Accelerate Start-up Times: Discover how a centralized approach to qualification can speed-up your vendor onboarding process by several months.
- Strengthen Regulatory Compliance: Understand how to implement a robust and consistent compliance program in a dynamic environment.
- Adaptive Vendor Risk Management: Build a dynamic risk management framework that spans qualification through oversight monitoring.
Download the recording and slides below
From Risk to Reward: A Next-Gen Approach to Vendor Risk Management
Speakers
Chris Casazza
Chief Commercial Officer, Diligent Pharma
23+ years of Commercialization and R&D commercial team leadership on the service side of the Pharma/BioPharma industry. Chris has held senior leadership positions at Kantar Health leading the US Client Consulting Services sales team, as well as Chief Commercial Officer of YourEncore with a transition to a leader of the Consulting organization at Advarra when acquired.
Anthea Dransfield
Head of Quality, Diligent Pharma
With over 30 years in the pharmaceutical industry, Anthea has held various operational and quality leadership roles, covering cGMP, clinical site operations, technical validation, and GxP quality oversight. Anthea advocates for risk-based, compliance-focused approaches and leverages technology to enhance quality processes.
Currently, Anthea leads Diligent’s quality and risk frameworks, ensuring effective business practices and high-quality work products.
Christopher Sallemi
Chief Technology Officer and Head of the Diligent Innovation Lab, Diligent Pharma
Chris brings almost 30 years of pharmaceutical industry experience, mainly at Eli Lilly & Co. His experiences include functional leadership roles in Clinical Laboratory Sciences, Clinical Data Sciences, eCOA/ePRO/Connected Devices/Digital Health, Clinical imaging, Decentralized Clinical Trials, Clinical Pharmacology and R&D Information Technology.
Chris has led organizations in the UK, Germany, Spain, Singapore, Japan and China.
Chris Otto
Quality Consultant, Diligent Pharma
Chris brings almost 30 years of pharmaceutical industry experience, mainly at Eli Lilly & Co. His experiences include functional leadership roles in Clinical Laboratory Sciences, Clinical Data Sciences, eCOA/ePRO/Connected Devices/Digital Health, Clinical imaging, Decentralized Clinical Trials, Clinical Pharmacology and R&D Information Technology.
Chris has led organizations in the UK, Germany, Spain, Singapore, Japan and China.